Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing

Reuters

08/19

Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing

Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab $(BOT.AU)$ and balstilimab $(BAL.AU)$ program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer $(CRC)$ studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2560419564"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560419564\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560419564?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-19 19:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560419564","market":"fut","top_or_hot":-1,"title":"Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab <a href=\"https://laohu8.com/S/BOT.AU\">$(BOT.AU)$</a> and balstilimab <a href=\"https://laohu8.com/S/BAL.AU\">$(BAL.AU)$</a> program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a> studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&amp;A, allowing for further engagement and clarification.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAgenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-19 19:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab <a href=\"https://laohu8.com/S/BOT.AU\">$(BOT.AU)$</a> and balstilimab <a href=\"https://laohu8.com/S/BAL.AU\">$(BAL.AU)$</a> program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer <a href=\"https://laohu8.com/S/CRC\">$(CRC)$</a> studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&amp;A, allowing for further engagement and clarification.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AGEN","symbol_name":"艾吉纳斯公司","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250819:nNDL8zzVK2:1","article_id":"2560419564","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560419564","pubTimestamp":1755603034,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab  and balstilimab  program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer  studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate a","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AGEN":"艾吉纳斯公司","BK4139":"生物科技"},"translate_title":"Agenus Inc.在即将举行的虚拟利益相关者简报会上宣布免疫肿瘤学领域的战略进展和关键里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AGEN":0.9},"content_text":"Agenus Inc. Announces Strategic Advancements and Key Milestones in Immuno-Oncology at Upcoming Virtual Stakeholder Briefing\n    \n\n        Agenus Inc., a prominent entity in the field of immuno-oncology, has announced a forthcoming virtual Stakeholder Briefing scheduled for August 27, 2025. During this event, the company plans to present strategic advancements and key milestones associated with its botensilimab $(BOT.AU)$ and balstilimab $(BAL.AU)$ program. The briefing will include a strategic and financial overview and highlight achievements related to the recently closed partnership with Zydus. It will also address growing interest in colorectal cancer $(CRC)$ studies, supported by recent data from the BOT/BAL program. Additionally, an overview of the Phase 3 BATTMAN study in metastatic CRC will be provided. Upcoming milestones and potential breakthroughs in the realm of immuno-oncology will also be discussed. The session will conclude with a live Q&A, allowing for further engagement and clarification.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agenus Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250819274234) on August 19, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}